A Phase II Evaluation of Ixabepilone (BMS-247550) [NCI-Supplied Agent, IND 59699, NSC 710428]) in the Treatment of Recurrent or Persistent Endometrial Carcinoma.

Trial Profile

A Phase II Evaluation of Ixabepilone (BMS-247550) [NCI-Supplied Agent, IND 59699, NSC 710428]) in the Treatment of Recurrent or Persistent Endometrial Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 May 2015

At a glance

  • Drugs Ixabepilone (Primary)
  • Indications Endometrial cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Feb 2008 Status change from recruiting to in progress.
    • 17 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top